Sep 18, 2026 03:26AM
Sep 18, 2026 03:25AM
Jul 29, 2026 01:00PM
Jul 29, 2026 01:00PM
Jul 22, 2026 01:00AM
Jul 22, 2026 01:00AM
Jul 22, 2026 01:00AM Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
May 20, 2026 07:15AM
May 16, 2026 08:00AM
Feb 27, 2026 06:20AM
Jan 21, 2026 11:45AM
Jan 13, 2026 12:19PM
Nov 7, 2025 08:50AM
Nov 7, 2025 08:42AM Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Sep 19, 2025 07:59AM
Jul 24, 2025 01:42PM
Jul 24, 2025 01:41PM
Jun 20, 2025 06:19AM
May 6, 2025 01:30AM
Apr 24, 2025 02:14AM
Sep 23, 2024 07:13AM Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
Jul 26, 2024 06:46AM
Jun 10, 2024 04:54PM
Jun 7, 2024 01:00AM
May 2, 2024 01:30AM
Apr 24, 2024 01:00AM
Feb 13, 2024 04:08PM
Dec 7, 2023 01:00AM Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
Nov 13, 2023 07:00AM
Oct 23, 2023 01:00AM
Sep 4, 2023 01:00AM
Sep 1, 2023 01:00AM
Aug 16, 2023 03:32PM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome  
Jul 19, 2023 12:42PM
Jun 28, 2023 08:00PM
Jun 14, 2023 04:35PM
Jun 14, 2023 02:21PM
Jun 13, 2023 01:10PM
Jun 12, 2023 01:00AM
May 26, 2023 08:20AM Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
Apr 27, 2023 01:00AM
Apr 24, 2023 02:00AM
Mar 16, 2023 02:02PM
Mar 2, 2023 02:13PM
Feb 15, 2023 01:00AM
Feb 13, 2023 05:00PM
Feb 9, 2023 01:00AM Ipsen presents strong full-year 2022 results and guidance for 2023
Jan 27, 2023 01:00AM

1,232,670 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All